Skip to Main Content

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies

Conditions

Non-Hodgkin's Lymphoma

Phase I

What is the purpose of this trial?

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas.

The study will have three parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors.

Find out more about who can participate in this trial
  • Trial with
    Seattle Genetics, Inc.
  • Start Date
    04/26/2022
  • End Date
    12/31/2022

For more information about this study, contact:

Laura Leary

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Sub-Investigators

  • Last Updated
    04/28/2022
  • Study HIC
    #2000027638

Contact Information

For more information about this study, including how to volunteer, contact Laura Leary

Volunteer Now